查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1344523

纖維肌痛治療市場：依藥物類別、通路劃分：2023-2032 年全球機會分析與產業預測

Fibromyalgia Treatment Market By Drug Class, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 233 Pages | 商品交期: 2-3個工作天內

價格

根據Allied Market Research發布的最新研究報告，由於製藥業的市場需求不斷增加，纖維肌痛治療市場預計從2023年至2032年將出現4.0%的顯著增長率。

纖維肌痛治療市場-IMG1

纖維肌痛症是一種慢性疾病，其特徵是身體各部位廣泛的肌肉骨骼疼痛、疲勞和壓痛。 纖維肌痛被認為是一種複雜的疾病，因為其確切原因尚不清楚，並且沒有針對纖維肌痛的明確診斷測試。 纖維肌痛的主要症狀是影響身體部位（例如肌肉、關節和軟組織）的慢性疼痛。 疼痛被描述為鈍痛、灼熱感或深層肌肉疼痛。 常伴隨疲勞、睡眠障礙、認知障礙、情緒障礙、觸覺敏感等症狀。 患有纖維肌痛的人可能會感到更劇烈的疼痛，或對通常不會引起其他人疼痛或不適的刺激做出反應。

纖維肌痛涉及中樞神經系統、神經傳導物質和大腦處理疼痛訊號的方式之間的複雜相互作用。 診斷纖維肌痛很困難，因為沒有特定的實驗室或影像檢查可以明確診斷纖維肌痛。 纖維肌痛的治療包括控制症狀並透過改善睡眠、保持健康飲食和運動以及使用緩解症狀的藥物來改善生活品質。重點是

全球纖維肌痛治療市場的成長主要是由纖維肌痛盛行率的驚人上升所推動的。 根據美國國家纖維肌痛協會 (2023) 的數據，纖維肌痛影響了美國約 1,000 萬人，盛行率為 75% 至 90%，主要是女性。 此外，纖維肌痛在中老年人中更為常見。 隨著世界人口老化，面臨纖維肌痛風險的人數將會增加，需要治療的患者人數也會增加。 因此，纖維肌痛盛行率的上升將推動對有效治療藥物的需求，進而推動市場成長。

目錄

第一章簡介

第 2 章執行摘要

第三章市場概述

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 族群中纖維肌痛的盛行率很高
      • 提高對纖維肌痛及其治療的認識
      • 改善獲得治療纖維肌痛的仿製藥的機會
    • 抑制因素
      • 替代治療方案的可用性
      • 發展中國家缺乏對纖維肌痛症的認識
    • 機會
      • 用於纖維肌痛治療的強大管道
  • 新冠肺炎 (COVID-19) 造成的市場影響分析

第 4 章纖維肌痛治療市場：依藥物類別

  • 抗憂鬱藥
  • 抗驚厥藥
  • 肌肉鬆弛劑
  • 其他

第 5 章纖維肌痛治療市場：依通路劃分

  • 醫院藥房
  • 藥局和零售藥局
  • 線上提供者

第 6 章纖維肌痛治療市場：依地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 韓國
    • 其他亞太地區
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他領域

第七章競爭態勢

  • 簡介
  • 關鍵成功策略
  • 10家主要公司的產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022 年主要公司的定位

第八章公司簡介

  • Abbott Laboratories
  • Amneal Pharmaceuticals LLC
  • Eli Lilly and Company
  • Lupin Limited.
  • Novartis AG
  • Viatris Inc.
  • Zydus Lifesciences Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.
Product Code: A13357

The fibromyalgia treatment market is likely to experience a significant growth rate of 4.0% from 2023-2032 owing to increasing market demand from pharmaceutical sector - Allied Market Research

Fibromyalgia Treatment Market - IMG1

Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, fatigue, and tenderness in various parts of the body. It is considered as a complex condition because its exact cause is not well understood, and there is no definitive diagnostic test for fibromyalgia. The primary symptom of fibromyalgia is chronic pain that affects body parts such as muscles, joints, and soft tissues. The pain may be described as a dull ache, a burning sensation, or a deep muscular soreness. It is often accompanied by other symptoms such as fatigue, sleep disturbances, cognitive difficulties, mood disorders, and heightened sensitivity to touch. People with fibromyalgia may experience pain more intensely or feel pain in response to stimuli that would not typically cause pain or discomfort in others.

It involves a complex interaction between the central nervous system, neurotransmitters, and the way pain signals are processed in the brain. Diagnosing fibromyalgia can be challenging as there are no specific laboratory tests or imaging studies that can definitively confirm the condition. Treatment for fibromyalgia focuses on managing symptoms and improving quality of life by using medications to alleviate the symptoms along with improving sleep and maintaining a healthy diet and exercise.

The growth of the global fibromyalgia treatment market is majorly driven by alarming rise in prevalence of fibromyalgia. According to the National Fibromyalgia Association (2023), fibromyalgia affects an estimated 10 million people in the U.S. and is mostly seen among women, with a prevalence of 75-90%. Moreover, fibromyalgia is more commonly diagnosed in middle-aged and older individuals. As the global population continues to age, the number of people at risk for developing fibromyalgia increases, leading to a larger patient pool requiring treatment. Thus, rise in prevalence of fibromyalgia boosts the demand for effective treatment medications, which, in turn, propels the growth of the market.

In addition, surge in awareness regarding fibromyalgia and its diagnosis and treatment among the people in developed countries acts as a major driver of the global market. Improved diagnosis and awareness have played a significant role in the identification and treatment of fibromyalgia. In the past, fibromyalgia was often misunderstood or misdiagnosed, leading to delayed or ineffective treatment for many individuals.

Moreover, in past few years, healthcare professionals and the general population have increasingly acknowledged and gained a better understanding of fibromyalgia condition. For instance, diagnostic criteria for fibromyalgia have evolved and become more refined. The American College of Rheumatology (ACR) has established updated diagnostic criteria, along with other assessment tools, which have helped healthcare professionals more accurately diagnose fibromyalgia. This will further significantly contribute to the growth of the fibromyalgia treatment market.

However, in addition to conventional medical approaches, certain individuals with fibromyalgia may explore alternative treatment options to help manage their symptoms. For instance, acupuncture and other therapies may be involved which hinder the market growth to some extent.

In addition, lack of knowledge and awareness about fibromyalgia in underdeveloped countries may have a negative impact on the growth of the market. In underdeveloped countries, there may be limited healthcare infrastructure, fewer trained healthcare professionals, and lack of specialized clinics or resources dedicated to chronic pain conditions such as fibromyalgia. This contribute to lack of awareness among both healthcare providers and the general population, which acts as a key deterrent factor of the global market.

On the contrary, a robust pipeline of products for fibromyalgia treatment presents an encouraging outlook for both patients and key players in the market. The development of new medications specifically targeting fibromyalgia holds the potential to address the unmet needs of patients and improve their quality of life. Continuous research and development efforts by pharmaceutical companies, researchers, and healthcare professionals demonstrate a commitment to finding more effective and safer treatment options for fibromyalgia. This includes exploring novel therapeutic approaches and investigating potential targeted therapies. Such strategies adopted by key players are anticipated to boost market growth during the forecast period.

In addition, emerging countries in Asia-Pacific and LAMEA present lucrative opportunities for key players looking to invest in the fibromyalgia treatment market. This is attributed to the fact that these regions are characterized by the presence of a large population base with notable economic growth and increase in healthcare expenditure. In addition, an alarming rise in prevalence of fibromyalgia in these regions along with rise in awareness about the condition is anticipated to drive the market growth.

The global fibromyalgia treatment market is segmented into drug class, distribution channel, and region. Depending on drug class, the market is categorized into antidepressants, anticonvulsants, muscle relaxants, and others. Based on distribution channel, it is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major players that operate in the market include Abbott Laboratories Abbvie Inc., Amneal Pharmaceuticals LLC, Eli Lilly and Company, Lupin, Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Viatris Inc., and Zydus Lifesciences Limited.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the fibromyalgia treatment market analysis from 2022 to 2032 to identify the prevailing fibromyalgia treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the fibromyalgia treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global fibromyalgia treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

  • Antidepressants
  • Anticonvulsants
  • Muscle Relaxants
  • Others

By Distribution Channel

  • Hospital pharmacies
  • Drug stores and retail pharmacies
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Abbott Laboratories
    • Teva Pharmaceutical Industries Ltd.
    • AbbVie Inc.
    • Amneal Pharmaceuticals LLC
    • Zydus Lifesciences Limited
    • Sun Pharmaceutical Industries Limited
    • Eli Lilly and Company
    • Novartis AG
    • Viatris Inc.
    • Lupin Limited.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Significant prevalence of fibromyalgia among the population
      • 3.4.1.2. Surge in awareness regarding fibromyalgia and its treatment
      • 3.4.1.3. Enhanced access to generic medications for fibromyalgia treatment
    • 3.4.2. Restraints
      • 3.4.2.1. Availability of alternate treatment options
      • 3.4.2.2. Lack of awareness about fibromyalgia in underdeveloped countries
    • 3.4.3. Opportunities
      • 3.4.3.1. Robust pipeline of products for fibromyalgia treatment
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Antidepressants
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Anticonvulsants
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Muscle Relaxants
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Hospital pharmacies
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Drug stores and retail pharmacies
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Online providers
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: FIBROMYALGIA TREATMENT MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key trends and opportunities
    • 6.2.2. Market size and forecast, by Drug Class
    • 6.2.3. Market size and forecast, by Distribution Channel
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Key market trends, growth factors and opportunities
      • 6.2.4.1.2. Market size and forecast, by Drug Class
      • 6.2.4.1.3. Market size and forecast, by Distribution Channel
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Key market trends, growth factors and opportunities
      • 6.2.4.2.2. Market size and forecast, by Drug Class
      • 6.2.4.2.3. Market size and forecast, by Distribution Channel
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Key market trends, growth factors and opportunities
      • 6.2.4.3.2. Market size and forecast, by Drug Class
      • 6.2.4.3.3. Market size and forecast, by Distribution Channel
  • 6.3. Europe
    • 6.3.1. Key trends and opportunities
    • 6.3.2. Market size and forecast, by Drug Class
    • 6.3.3. Market size and forecast, by Distribution Channel
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Key market trends, growth factors and opportunities
      • 6.3.4.1.2. Market size and forecast, by Drug Class
      • 6.3.4.1.3. Market size and forecast, by Distribution Channel
      • 6.3.4.2. France
      • 6.3.4.2.1. Key market trends, growth factors and opportunities
      • 6.3.4.2.2. Market size and forecast, by Drug Class
      • 6.3.4.2.3. Market size and forecast, by Distribution Channel
      • 6.3.4.3. UK
      • 6.3.4.3.1. Key market trends, growth factors and opportunities
      • 6.3.4.3.2. Market size and forecast, by Drug Class
      • 6.3.4.3.3. Market size and forecast, by Distribution Channel
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Key market trends, growth factors and opportunities
      • 6.3.4.4.2. Market size and forecast, by Drug Class
      • 6.3.4.4.3. Market size and forecast, by Distribution Channel
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Key market trends, growth factors and opportunities
      • 6.3.4.5.2. Market size and forecast, by Drug Class
      • 6.3.4.5.3. Market size and forecast, by Distribution Channel
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Key market trends, growth factors and opportunities
      • 6.3.4.6.2. Market size and forecast, by Drug Class
      • 6.3.4.6.3. Market size and forecast, by Distribution Channel
  • 6.4. Asia-Pacific
    • 6.4.1. Key trends and opportunities
    • 6.4.2. Market size and forecast, by Drug Class
    • 6.4.3. Market size and forecast, by Distribution Channel
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Key market trends, growth factors and opportunities
      • 6.4.4.1.2. Market size and forecast, by Drug Class
      • 6.4.4.1.3. Market size and forecast, by Distribution Channel
      • 6.4.4.2. China
      • 6.4.4.2.1. Key market trends, growth factors and opportunities
      • 6.4.4.2.2. Market size and forecast, by Drug Class
      • 6.4.4.2.3. Market size and forecast, by Distribution Channel
      • 6.4.4.3. India
      • 6.4.4.3.1. Key market trends, growth factors and opportunities
      • 6.4.4.3.2. Market size and forecast, by Drug Class
      • 6.4.4.3.3. Market size and forecast, by Distribution Channel
      • 6.4.4.4. Australia
      • 6.4.4.4.1. Key market trends, growth factors and opportunities
      • 6.4.4.4.2. Market size and forecast, by Drug Class
      • 6.4.4.4.3. Market size and forecast, by Distribution Channel
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Key market trends, growth factors and opportunities
      • 6.4.4.5.2. Market size and forecast, by Drug Class
      • 6.4.4.5.3. Market size and forecast, by Distribution Channel
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Key market trends, growth factors and opportunities
      • 6.4.4.6.2. Market size and forecast, by Drug Class
      • 6.4.4.6.3. Market size and forecast, by Distribution Channel
  • 6.5. LAMEA
    • 6.5.1. Key trends and opportunities
    • 6.5.2. Market size and forecast, by Drug Class
    • 6.5.3. Market size and forecast, by Distribution Channel
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Key market trends, growth factors and opportunities
      • 6.5.4.1.2. Market size and forecast, by Drug Class
      • 6.5.4.1.3. Market size and forecast, by Distribution Channel
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Key market trends, growth factors and opportunities
      • 6.5.4.2.2. Market size and forecast, by Drug Class
      • 6.5.4.2.3. Market size and forecast, by Distribution Channel
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Key market trends, growth factors and opportunities
      • 6.5.4.3.2. Market size and forecast, by Drug Class
      • 6.5.4.3.3. Market size and forecast, by Distribution Channel
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Key market trends, growth factors and opportunities
      • 6.5.4.4.2. Market size and forecast, by Drug Class
      • 6.5.4.4.3. Market size and forecast, by Distribution Channel

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. Abbott Laboratories
    • 8.1.1. Company overview
    • 8.1.2. Key Executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
  • 8.2. Amneal Pharmaceuticals LLC
    • 8.2.1. Company overview
    • 8.2.2. Key Executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
    • 8.2.7. Key strategic moves and developments
  • 8.3. Eli Lilly and Company
    • 8.3.1. Company overview
    • 8.3.2. Key Executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
  • 8.4. Lupin Limited.
    • 8.4.1. Company overview
    • 8.4.2. Key Executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
    • 8.4.7. Key strategic moves and developments
  • 8.5. Novartis AG
    • 8.5.1. Company overview
    • 8.5.2. Key Executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
    • 8.5.7. Key strategic moves and developments
  • 8.6. Viatris Inc.
    • 8.6.1. Company overview
    • 8.6.2. Key Executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
  • 8.7. Zydus Lifesciences Limited
    • 8.7.1. Company overview
    • 8.7.2. Key Executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
    • 8.7.7. Key strategic moves and developments
  • 8.8. Sun Pharmaceutical Industries Limited
    • 8.8.1. Company overview
    • 8.8.2. Key Executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
  • 8.9. Teva Pharmaceutical Industries Ltd.
    • 8.9.1. Company overview
    • 8.9.2. Key Executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
  • 8.10. AbbVie Inc.
    • 8.10.1. Company overview
    • 8.10.2. Key Executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance
    • 8.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 02. FIBROMYALGIA TREATMENT MARKET FOR ANTIDEPRESSANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. FIBROMYALGIA TREATMENT MARKET FOR ANTICONVULSANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. FIBROMYALGIA TREATMENT MARKET FOR MUSCLE RELAXANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. FIBROMYALGIA TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 07. FIBROMYALGIA TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. FIBROMYALGIA TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. FIBROMYALGIA TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. FIBROMYALGIA TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 14. U.S. FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 15. U.S. FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. CANADA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 17. CANADA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 18. MEXICO FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 19. MEXICO FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 23. GERMANY FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 24. GERMANY FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 25. FRANCE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 26. FRANCE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. UK FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 28. UK FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. ITALY FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 30. ITALY FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 31. SPAIN FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 32. SPAIN FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. REST OF EUROPE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 34. REST OF EUROPE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 35. ASIA-PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 38. JAPAN FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 39. JAPAN FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. CHINA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 41. CHINA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. INDIA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 43. INDIA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 44. AUSTRALIA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 45. AUSTRALIA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. SOUTH KOREA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 47. SOUTH KOREA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. REST OF ASIA-PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 49. REST OF ASIA-PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. LAMEA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 51. LAMEA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. LAMEA FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. BRAZIL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 54. BRAZIL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. SAUDI ARABIA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 56. SAUDI ARABIA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 57. SOUTH AFRICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 58. SOUTH AFRICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. REST OF LAMEA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 60. REST OF LAMEA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 62. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 63. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 64. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 65. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 66. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 67. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
  • TABLE 68. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 69. AMNEAL PHARMACEUTICALS LLC: KEY STRATERGIES
  • TABLE 70. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 71. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 72. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
  • TABLE 73. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 74. LUPIN LIMITED.: KEY EXECUTIVES
  • TABLE 75. LUPIN LIMITED.: COMPANY SNAPSHOT
  • TABLE 76. LUPIN LIMITED.: PRODUCT SEGMENTS
  • TABLE 77. LUPIN LIMITED.: PRODUCT PORTFOLIO
  • TABLE 78. LUPIN LIMITED.: KEY STRATERGIES
  • TABLE 79. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 80. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 81. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 82. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 83. NOVARTIS AG: KEY STRATERGIES
  • TABLE 84. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 85. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 86. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 87. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 88. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
  • TABLE 89. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
  • TABLE 90. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
  • TABLE 91. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
  • TABLE 92. ZYDUS LIFESCIENCES LIMITED: KEY STRATERGIES
  • TABLE 93. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 94. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 95. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 96. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 97. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 98. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 99. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 100. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 101. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 102. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 103. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 104. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 105. ABBVIE INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. FIBROMYALGIA TREATMENT MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF FIBROMYALGIA TREATMENT MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN FIBROMYALGIA TREATMENT MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALFIBROMYALGIA TREATMENT MARKET
  • FIGURE 10. FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF FIBROMYALGIA TREATMENT MARKET FOR ANTIDEPRESSANTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF FIBROMYALGIA TREATMENT MARKET FOR ANTICONVULSANTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF FIBROMYALGIA TREATMENT MARKET FOR MUSCLE RELAXANTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF FIBROMYALGIA TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF FIBROMYALGIA TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF FIBROMYALGIA TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF FIBROMYALGIA TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. FIBROMYALGIA TREATMENT MARKET BY REGION, 2022
  • FIGURE 20. U.S. FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 21. CANADA FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 22. MEXICO FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. GERMANY FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. FRANCE FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. UK FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. ITALY FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. SPAIN FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. REST OF EUROPE FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. JAPAN FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. CHINA FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. INDIA FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. AUSTRALIA FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. SOUTH KOREA FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. REST OF ASIA-PACIFIC FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. BRAZIL FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SAUDI ARABIA FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SOUTH AFRICA FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF LAMEA FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 42. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 43. COMPETITIVE DASHBOARD
  • FIGURE 44. COMPETITIVE HEATMAP: FIBROMYALGIA TREATMENT MARKET
  • FIGURE 45. TOP PLAYER POSITIONING, 2022
  • FIGURE 46. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 48. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 49. AMNEAL PHARMACEUTICALS LLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 51. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. LUPIN LIMITED.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. LUPIN LIMITED.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 60. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 61. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 62. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 63. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 64. SUN PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 65. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 66. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 67. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 68. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 69. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)